Hyperion DeFi, Inc. (HYPD) 10-Year Financial Performance & Capital Metrics

HYPD • • Industrial / General

HealthcareMedical DevicesSurgical & Minimally Invasive DevicesSurgical Energy & Ablation Systems

AboutA U.S.-based firm pivoting from ophthalmic drug-delivery tech (Optejet) to becoming the first Nasdaq-listed U.S. company with a cryptocurrency treasury denominated in HYPE tokens from the Hyperliquid blockchain; also operates a validator (“Kinetiq × Hyperion”) and continues DeFi staking strategies alongside ongoing development of Optejet UFD™ for eye care.Show more

Revenue $57K +1414.0%
EBITDA -$48M -93.4%
Net Income -$50M -82.7%
EPS (Diluted) -59.81 -12.5%
Gross Margin -6749.5% -1992.0%
EBITDA Margin -83036.44% +87.2%
Operating Margin -85004.58% +87.3%
Net Margin -86888.57% +87.9%
ROE -
ROIC -1168.88% -351.6%
Debt/Equity -
Interest Coverage -19.62 -83.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 8 (bottom 8%)
✗Shares diluted 62.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-84%

TTM984.82%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM32.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM33.99%

ROCE

10Y Avg-368.44%

5Y Avg-368.44%

3Y Avg-548.09%

Latest-1418.76%

Peer Comparison

Surgical Energy & Ablation Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
BDMDBaird Medical Investment Holdings Limited	47.38M	1.29	2.63	17.74%	33.62%	33%	0.53
IVFINVO Fertility, Inc.	12.26M	0.81	-0.03	116.25%	-417.01%	-495.09%	0.78
AEMDAethlon Medical, Inc.	2.55M	2.62	-0.03			-0.2%	0.13
HYPDHyperion DeFi, Inc.	29.01M	3.55	-0.06	14.14%	-73.86%	-36.05%
NAOVNanoVibronix, Inc.	1.85M	1.70	-0.12	12.05%	-133.04%	-8.41%	0.19
ALURAllurion Technologies Inc.	21.55M	1.76	-0.15	-39.94%	-251.56%
RBOTVicarious Surgical Inc.	18.23M	2.82	-0.26			-380.42%	0.30
TELATELA Bio, Inc.	44.98M	1.01	-0.76	18.56%	-50.61%	-25.05%	1.51

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2M	14M	0	3.79K	57.34K
Revenue Growth %	-	6%	-1%	-	14.14%
Cost of Goods Sold+	800K	1.6M	0	16K	3.93M
COGS % of Revenue	0.4%	0.11%	-	4.23%	68.49%
Gross Profit+	1.2M	12.4M	0	-12.22K	-3.87M
Gross Margin %	0.6%	0.89%	-	-3.23%	-67.49%
Gross Profit Growth %	-	9.33%	-1%	-	-315.74%
Operating Expenses+	20.99M	25.42M	26.91M	25.39M	44.87M
OpEx % of Revenue	10.49%	1.82%	-	6705.63%	782.55%
Selling, General & Admin	7.69M	10.57M	13.53M	12.42M	14.33M
SG&A % of Revenue	3.84%	0.75%	-	3279.22%	249.98%
Research & Development	13.36M	14.85M	13.38M	12.98M	14.46M
R&D % of Revenue	6.68%	1.06%	-	3426.41%	252.25%
Other Operating Expenses	-59.72K	1	0	0	16.07M
Operating Income+	-19.79M	-13.02M	-26.91M	-25.41M	-48.74M
Operating Margin %	-9.89%	-0.93%	-	-6708.86%	-850.05%
Operating Income Growth %	-	0.34%	-1.07%	0.06%	-0.92%
EBITDA+	-19.69M	-12.8M	-26.6M	-24.62M	-47.61M
EBITDA Margin %	-9.85%	-0.91%	-	-6502.04%	-830.36%
EBITDA Growth %	-	0.35%	-1.08%	0.07%	-0.93%
D&A (Non-Cash Add-back)	95.42K	221.56K	307.43K	783.21K	1.13M
EBIT	-19.79M	-12.39M	-26.63M	-24.89M	-47.33M
Net Interest Income+	9.36K	-385.24K	-1.3M	-1.68M	-2.23M
Interest Income	26.4K	2.52K	83.33K	693.61K	254.02K
Interest Expense	17.04K	387.76K	1.38M	2.37M	2.48M
Other Income/Expense	19.36K	242.14K	-1.1M	-1.85M	-1.08M
Pretax Income+	-19.77M	-12.78M	-28.01M	-27.26M	-49.82M
Pretax Margin %	-9.88%	-0.91%	-	-7198.6%	-868.89%
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-19.77M	-12.78M	-28.01M	-27.26M	-49.82M
Net Margin %	-9.88%	-0.91%	-	-7198.6%	-868.89%
Net Income Growth %	-	0.35%	-1.19%	0.03%	-0.83%
Net Income (Continuing)	-19.77M	-12.78M	-28.01M	-27.26M	-49.82M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-75.20	-39.20	-66.40	-53.15	-59.81
EPS Growth %	-	0.48%	-0.69%	0.2%	-0.13%
EPS (Basic)	-75.12	-39.20	-66.40	-53.15	-59.81
Diluted Shares Outstanding	263.18K	329.05K	420.62K	512.91K	833K
Basic Shares Outstanding	262.9K	329.05K	420.62K	512.91K	833K
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	33.39M	22M	27.64M	20.71M	2.77M
Cash & Short-Term Investments	28.37M	19.46M	22.86M	14.85M	2.12M
Cash Only	28.37M	19.46M	22.86M	14.85M	2.12M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	2.97M	1.81M	1.18M	123.83K	24.83K
Days Sales Outstanding	541.3	47.06	-	11.94K	158.05
Inventory	0	0	0	109.8K	0
Days Inventory Outstanding	-	-	-	2.5K	-
Other Current Assets	1.82M	348.31K	3.09M	5.18M	341.36K
Total Non-Current Assets+	515.41K	9.66M	3.39M	8.07M	900.56K
Property, Plant & Equipment	396.38K	1.27M	2.59M	5.04M	718.36K
Fixed Asset Turnover	5.05x	11.01x	-	0.00x	0.08x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	2.12M	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	119.03K	8.39M	807.2K	908.61K	182.2K
Total Assets+	33.91M	31.66M	31.04M	28.78M	3.67M
Asset Turnover	0.06x	0.44x	-	0.00x	0.02x
Asset Growth %	-	-0.07%	-0.02%	-0.07%	-0.87%
Total Current Liabilities+	18.2M	11.17M	4.51M	9.53M	16.05M
Accounts Payable	1.46M	1.61M	1.43M	1.75M	2.2M
Days Payables Outstanding	666.88	368.22	-	39.98K	204.45
Short-Term Debt	97.54K	7.15M	348.9K	5.33M	9.95M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	14.06M	81.09K	147.55K	135.03K	2.98M
Current Ratio	1.83x	1.97x	6.13x	2.17x	0.17x
Quick Ratio	1.83x	1.97x	6.13x	2.16x	0.17x
Cash Conversion Cycle	-	-	-	-25.54K	-
Total Non-Current Liabilities+	404.5K	19.95K	9.29M	10.25M	717.5K
Long-Term Debt	365.81K	0	8.38M	8.96M	0
Capital Lease Obligations	0	0	907.64K	1.29M	717.5K
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	38.68K	19.95K	0	0	1
Total Liabilities	18.6M	11.19M	13.8M	19.78M	16.76M
Total Debt+	463.35K	7.15M	10.12M	16.08M	11.24M
Net Debt	-27.91M	-12.31M	-12.74M	1.23M	9.12M
Debt / Equity	0.03x	0.35x	0.59x	1.79x	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-1161.20x	-33.58x	-19.50x	-10.71x	-19.62x
Total Equity+	15.3M	20.47M	17.23M	9M	-13.1M
Equity Growth %	-	0.34%	-0.16%	-0.48%	-2.46%
Book Value per Share	58.15	62.20	40.97	17.55	-15.72
Total Shareholders' Equity	15.3M	20.47M	17.23M	9M	-13.1M
Common Stock	2.5K	2.84K	3.67K	57	151
Retained Earnings	-77.44M	-90.22M	-118.23M	-145.49M	-195.31M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.38M	-20.87M	-25.11M	-23.84M	-30.12M
Operating CF Margin %	-3.19%	-1.49%	-	-6294.31%	-525.34%
Operating CF Growth %	-	-2.27%	-0.2%	0.05%	-0.26%
Net Income	-19.77M	-12.78M	-28.01M	-27.26M	-49.82M
Depreciation & Amortization	95.42K	221.56K	307.43K	783.21K	1.13M
Stock-Based Compensation	2.48M	2.89M	3.77M	2.5M	1.7M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	-79.69K	-501.76K	1.1M	1.62M	17.2M
Working Capital Changes	10.89M	-10.7M	-2.26M	-1.48M	-339.82K
Change in Receivables	0	1.4M	621.28K	1.06M	99.01K
Change in Inventory	0	0	0	-122.02K	0
Change in Payables	0	126.11K	-185.82K	324.89K	446.6K
Cash from Investing+	-261.26K	-1.62M	-874.75K	-3.97M	-161.48K
Capital Expenditures	-261.26K	-1.62M	-874.75K	-2.85M	-161.48K
CapEx % of Revenue	0.13%	0.12%	-	751.94%	2.82%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	-1.12M	0
Cash from Financing+	20.86M	21.46M	21.51M	19.79M	17.55M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	20.88M	1.88M	-744.2K	-1.31M	-2.56M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-6.65M	-22.49M	-25.98M	-27.81M	-30.28M
FCF Margin %	-3.32%	-1.61%	-	-7342.77%	-528.16%
FCF Growth %	-	-2.38%	-0.16%	-0.07%	-0.09%
FCF per Share	-25.25	-68.36	-61.77	-54.21	-36.35
FCF Conversion (FCF/Net Income)	0.32x	1.63x	0.90x	0.87x	0.60x
Interest Paid	13.97K	227.17K	315.55K	1.69M	1.62M
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-129.18%	-71.45%	-148.6%	-207.83%	-
Return on Invested Capital (ROIC)	-	-	-319.12%	-258.81%	-1168.88%
Gross Margin	60%	88.57%	-	-322.63%	-6749.5%
Net Margin	-988.49%	-91.27%	-	-719859.94%	-86888.57%
Debt / Equity	0.03x	0.35x	0.59x	1.79x	-
Interest Coverage	-1161.20x	-33.58x	-19.50x	-10.71x	-19.62x
FCF Conversion	0.32x	1.63x	0.90x	0.87x	0.60x
Revenue Growth	-	600%	-100%	-	1414.02%

Frequently Asked Questions

Growth & Financials

Hyperion DeFi, Inc. (HYPD) reported $0.3M in revenue for fiscal year 2024. This represents a 83% decrease from $2.0M in 2020.

Hyperion DeFi, Inc. (HYPD) grew revenue by 1414.0% over the past year. This is strong growth.

Hyperion DeFi, Inc. (HYPD) reported a net loss of $25.5M for fiscal year 2024.

Dividend & Returns

Hyperion DeFi, Inc. (HYPD) had negative free cash flow of $62.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener